News

Press Releases

August 13, 2020
Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series
June 27, 2020
Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
June 17, 2020
Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
June 11, 2020
Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
See all

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com

Presentations and Publications

See all

In the News

August 14, 2020
How a biotech CEO figured out Covid-19 surveillance testing for 50 companies with 12-hour turnaround times
CNBC
August 13, 2020
COVID-19 testing to keep employees safe
CNBC
June 29, 2020
Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks
Endpoints News
June 27, 2020
In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys
STAT News
See all
 

Stay Connected

Find us on LinkedIn and Twitter